ArticleDiabetology & metabolic syndrome2025
Prognostic impacts of lipoxin A4 in relation to diabetes and insulin resistance in patients with acute myocardial infarction: a prospective study.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsTo investigate whether the prognostic impact of lipoxin A4 (LXA4) is affected by diabetes mellitus (DM) and insulin resistance (IR), as indicated by the triglyceride-glucose index (TyG). MATERIALS AND
methodsA total of 1569 consecutive patients with acute myocardial infarction (AMI) were prospectively recruited between March 2017 and January 2020. Plasma LXA4 levels were determined using enzyme-linked immunosorbent assay. Patients were stratified into four groups according to DM and TyG (high vs. low). The primary outcome was major adverse cardiovascular event (MACE), a composite of all-cause death, recurrent MI, ischemic stroke, and ischemia-driven revascularizations.
resultsHigh levels of LXA4 (≥ 5.637 ng/mL) were associated lower risk of MACE (hazard ratio [HR]: 0.42, 95% confidence interval [CI]: 0.28-0.65, P < 0.001) in non-DM patients with low TyG (< 5.461) after multiple adjustments, which was not observed in patients with DM or high TyG (P
conclusionIn patients with AMI, ischemic risk reduction associated with high LXA4 levels is attenuated by DM and IR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.